Company Performance Metrics
- Stella Sarraf: Chief Executive Officer, Founder & Director
Amydis is a privately-held pharmaceutical company focused on developing innovative chemistry to detect diseases that involve the presence of amyloid proteins. Our mission is to develop a universal, non-invasive diagnostic that is faster, more accessible, and more affordable than current tests for diseases with unmet clinical and medical needs.
Amydis has a platform of novel compounds that fluoresces when bound to amyloid proteins, thus enabling diagnosis of such diseases.
The Company’s most advanced program is targeting the detection of early stage Alzheimer’s disease, a well-known amyloid disease. Other potential development programs include the detection of Parkinson’s disease, Creutzfeldt-Jakob disease (mad cow disease), Pre-eclampsia, TTR Amyloidosis, and Cerebral Amyloid Angiopathy, all of which are associated with the presence of amyloid protein.
Amydis offers you and your loved ones the ability to know whether you are at risk for Alzheimer’s or other amyloid-associated diseases. Knowing will allow you and your healthcare professional to make the right decisions.
